Targeting the USP1/PLK1 axis with NTUZLB-001 represents a promising therapeutic strategy to overcome drug resistance and enhance the clinical efficacy of Lenvatinib in HCC treatment. Here, USP1 is linked to hepatocellular carcinoma.